Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

• Authors: ENGELHARDT M.; KLEBER M.; UDI J.; WÄSCH R.; SPENCER A.; PATRIARCA F.; KNOP S.; BRUNO B.; GRAMATZKI M.; MORABITO F.; KROPFF M.; ROSELLI Amneris; SEZER O.; HÁJEK Roman; BUNJES D.; BOCCADORO M.; STRAKA C.; CAVO M.; POLLIACK A.; EINSELE H.; PALUMBO A.
• Year of publication: 2010
• Type: Article in Periodical
• Magazine / Source: Leukemia & lymphoma
• MU Faculty or unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3109/10428194.2010.487959
• Field: Oncology and hematology
• Keywords: multiple myeloma; therapy
• Description: Treatment for multiple myeloma (MM) has changed beyond recognition over the past two decades. During the early 1980s, MM inevitably resulted in a slow progressive decline in quality of life until death after about 2 years, while today patients can expect a 50% chance of achieving a complete remission, median survival of 5 years, and a 20% chance of surviving longer than 10 years. An international expert opinion meeting (including members of the GIMEMA and DSMM study groups) was held in 2009. One of the outcomes of the meeting was the development of a consensus statement outlining contemporary optimal clinical practice for the treatment of MM. This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM.